Navigation Links
Phoenix conference highlights TGen's and Scottsdale Healthcare's contributions to molecular oncology
Date:1/9/2009

PHOENIX, Ariz. Jan. 8, 2009 Physician-scientists from the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare will present their latest findings and techniques at a national conference designed to provide cancer doctors with new treatments for their patients.

"Molecular Oncology: The Sixth Vital Sign, What Every Oncologist Should Know" is intended to help cancer doctors provide better diagnosis, early detection as well as drugs and other treatments that in some cases can slow the growth or even shrink tumors.

"Given the explosion of new information on the genetic and cellular features of malignancy, the modern oncologist must master the significance and application of cancer-related sciences,'' said Dr. Ramesh K. Ramanathan, Medical Director of TGen Clinical Research Services at Scottsdale Healthcare, a partnership between TGen and Scottsdale Healthcare Corp.

Beyond the five vital signs of pulse, respiration, temperature, blood pressure and pain, is a new sixth vital sign molecular therapeutics. This is the ability to identify the causes of disease at the molecular level in order to provide the right drugs in the right amounts at the right times for the specific needs of individual patients; what is becoming better known in health circles as personalized medicine.

"This gap in knowledge and its application in clinical practice will be addressed in this conference,'' said Dr. Ramanathan, a Senior Investigator at TGen.

Dr. Ramanathan is the co-program director of the conference, along with Dr. Daniel Von Hoff, TGen's Physician-In-Chief and the Chief Scientific Officer at TCRS. Both doctors conduct groundbreaking personalized-medicine research and clinical drug trials at TCRS in Scottsdale, and both are on the clinical faculty of the University of Arizona College of Medicine. Both will present at the conference.

Other TGen and Scottsdale Healthcare scientists scheduled to present include: Dr. Jeffrey Trent, TGen's President and Scientific Director; Dr. Raoul Tibes, Director of the Hematological Malignancies Program at TCRS and an Associate Investigator at TGen; Dr. Stephen P. Anthony, Chief Medical Officer of TGen Drug Development Services (TD2) and a Senior Investigator at TGen; Dr. John Carpten, Director of TGen's Integrated Cancer Genomics Division and a Senior Investigator at TGen; and Gayle Jameson, M.S.N., Director of Supportive Care at TCRS and an Associate Investigator at TGen.

Besides oncologists, the target audience includes all physicians and health professionals involved in caring for cancer patients, and researchers interested in new cancer diagnostics and therapeutics.

Key objectives of the conference include:

  • Explaining the molecular and cellular features of malignancy in diagnostic and therapeutic approaches to the treatment of cancer, and identifying new diagnostic tools.

  • Assessing the effects and early clinical results of new, targeted drug therapies on solid tumors and malignant blood cancers.

  • Identifying new drug therapies that optimize treatment results and minimize side effects in specific biologic and clinical scenarios.

  • Evaluating clinical trials and translational methods of care and their proper use in clinical decision-making and patient management.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Phoenix mission to Mars will search for climate clues
2. Atmel and Phoenix Technologies Collaborate to Create Next-generation Security Solutions for PCs
3. Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs
4. Harmonizing Biobank Research Conference in 2009
5. PNNL researchers earn top honors at Supercomputing conference
6. Conference to explore sustainability of biofuels
7. Animal and biological science highlights: San Antonio Fluid Dynamics Conference, Nov. 23-25
8. Major conference on food Dec. 1-2, 2008
9. PNNL leadership in carbon sequestration featured at international conference
10. Engineer to present leak-proof method for carbon dioxide storage at international conference
11. Marine invasive species advance 50 km per decade, World Conference on Marine Biodiversity told
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... England , January 23, 2017 ... today announces completion of its Series D financing, raising $35 ... one new investor, Wondfo Biotech. ... Development of the Atlas Genetics io® ... the Chlamydia trachomatis (CT) test announced in February 2016.  This ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L ... the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices ... and scientific consultants and contractors. This is the latest step in G&L’s expansion ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
Breaking Biology Technology: